Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations

Journal of Medicinal Chemistry

Volumn 61, Issue 1, 2018, Pages 1-46

  Lee, Yoonji ^a   Basith, Shaherin ^a   Choi, Sun ^a  

^a Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 40; LYSOPHOSPHOLIPID RECEPTOR; MUSCARINIC RECEPTOR; NEUROTENSIN RECEPTOR; NOCICEPTIN RECEPTOR; OPIATE RECEPTOR; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; SEROTONIN RECEPTOR;

ALLOSTERISM; COMPUTER SIMULATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG MECHANISM; HUMAN; LIGAND BINDING; NONHUMAN; REVIEW; ANIMAL; CHEMISTRY; METABOLISM; X RAY CRYSTALLOGRAPHY;

ANIMALS; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85041612964     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01453     Document Type: Review

References (211)

1. Conn, P. M.; Ulloa-Aguirre, A.; Ito, J.; Janovick, J. A. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo Pharmacol. Rev. 2007, 59, 225-250 10.1124/pr.59.3.2
2. Thomsen, W.; Frazer, J.; Unett, D. Functional assays for screening GPCR targets Curr. Opin. Biotechnol. 2005, 16, 655-665 10.1016/j.copbio.2005.10.008
3. Schoneberg, T.; Hofreiter, M.; Schulz, A.; Rompler, H. Learning from the past: evolution of GPCR functions Trends Pharmacol. Sci. 2007, 28, 117-121 10.1016/j.tips.2007.01.001
4. Foord, S. M.; Bonner, T. I.; Neubig, R. R.; Rosser, E. M.; Pin, J. P.; Davenport, A. P.; Spedding, M.; Harmar, A. J. International union of pharmacology. XLVI. G protein-coupled receptor list Pharmacol. Rev. 2005, 57, 279-288 10.1124/pr.57.2.5
5. Ghosh, E.; Kumari, P.; Jaiman, D.; Shukla, A. K. Methodological advances: the unsung heroes of the GPCR structural revolution Nat. Rev. Mol. Cell Biol. 2015, 16, 69-81 10.1038/nrm3933
6. Deupi, X. Relevance of rhodopsin studies for GPCR activation Biochim. Biophys. Acta, Bioenerg. 2014, 1837, 674-682 10.1016/j.bbabio.2013.09.002
7. Hanlon, C. D.; Andrew, D. J. Outside-in signaling - a brief review of GPCR signaling with a focus on the Drosophila GPCR family J. Cell Sci. 2015, 128, 3533-3542 10.1242/jcs.175158
8. Zhang, D.; Zhao, Q.; Wu, B. Structural studies of G protein-coupled receptors Mol. Cells 2015, 38, 836-842 10.14348/molcells.2015.0263
9. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors Endocr. Rev. 2000, 21, 90-113 10.1210/edrv.21.1.0390
10. Salon, J. A.; Lodowski, D. T.; Palczewski, K. The significance of G protein-coupled receptor crystallography for drug discovery Pharmacol. Rev. 2011, 63, 901-937 10.1124/pr.110.003350
11. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors Methods Neurosci. 1995, 25, 366-428 10.1016/S1043-9471(05)80049-7
12. Katritch, V.; Cherezov, V.; Stevens, R. C. Diversity and modularity of G protein-coupled receptor structures Trends Pharmacol. Sci. 2012, 33, 17-27 10.1016/j.tips.2011.09.003
13. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor Science 2007, 318, 1258-1265 10.1126/science.1150577
14. Xiang, J.; Chun, E.; Liu, C.; Jing, L.; Al-Sahouri, Z.; Zhu, L.; Liu, W. Successful strategies to determine high-resolution structures of GPCRs Trends Pharmacol. Sci. 2016, 37, 1055-1069 10.1016/j.tips.2016.09.009
15. Robertson, N.; Jazayeri, A.; Errey, J.; Baig, A.; Hurrell, E.; Zhukov, A.; Langmead, C. J.; Weir, M.; Marshall, F. H. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery Neuropharmacology 2011, 60, 36-44 10.1016/j.neuropharm.2010.07.001
16. Cvicek, V.; Goddard, W. A.; Abrol, R. Structure-based sequence alignment of the transmembrane domains of all human GPCRs: phylogenetic, structural and functional implications PLoS Comput. Biol. 2016, 12, 1-31 10.1371/journal.pcbi.1004805
17. Strosberg, A. D. Structure, function, and regulation of adrenergic receptors Protein Sci. 1993, 2, 1198-1209 10.1002/pro.5560020802
18. Christopher, J. A.; Brown, J.; Dore, A. S.; Errey, J. C.; Koglin, M.; Marshall, F. H.; Myszka, D. G.; Rich, R. L.; Tate, C. G.; Tehan, B.; Warne, T.; Congreve, M. Biophysical fragment screening of the beta1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design J. Med. Chem. 2013, 56, 3446-3455 10.1021/jm400140q
19. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor Nature 2007, 450, 383-387 10.1038/nature06325
20. Hanson, M. A.; Cherezov, V.; Griffith, M. T.; Roth, C. B.; Jaakola, V. P.; Chien, E. Y. T.; Velasquez, J.; Kuhn, P.; Stevens, R. C. A specific cholesterol binding site is established by the 2.8 angstrom structure of the human beta2-adrenergic receptor Structure 2008, 16, 897-905 10.1016/j.str.2008.05.001
21. Wacker, D.; Fenalti, G.; Brown, M. A.; Katritch, V.; Abagyan, R.; Cherezov, V.; Stevens, R. C. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography J. Am. Chem. Soc. 2010, 132, 11443-11445 10.1021/ja105108q
22. Zou, Y.; Weis, W. I.; Kobilka, B. K. N-terminal T4 lysozyme fusion facilitates crystallization of a G protein coupled receptor PLoS One 2012, 7, e46039 10.1371/journal.pone.0046039
23. Huang, C. Y.; Olieric, V.; Ma, P.; Howe, N.; Vogeley, L.; Liu, X. Y.; Warshamanage, R.; Weinert, T.; Panepucci, E.; Kobilka, B.; Diederichs, K.; Wang, M. T.; Caffrey, M. In meso in situ serial X-ray crystallography of soluble and membrane proteins at cryogenic temperatures Acta Crystallogr., Sect. D: Struct. Biol. 2016, 72, 93-112 10.1107/S2059798315021683
24. Rosenbaum, D. M.; Zhang, C.; Lyons, J. A.; Holl, R.; Aragao, D.; Arlow, D. H.; Rasmussen, S. G.; Choi, H. J.; Devree, B. T.; Sunahara, R. K.; Chae, P. S.; Gellman, S. H.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Caffrey, M.; Gmeiner, P.; Kobilka, B. K. Structure and function of an irreversible agonist-beta2 adrenoceptor complex Nature 2011, 469, 236-240 10.1038/nature09665
25. Weichert, D.; Kruse, A. C.; Manglik, A.; Hiller, C.; Zhang, C.; Hubner, H.; Kobilka, B. K.; Gmeiner, P. Covalent agonists for studying G protein-coupled receptor activation Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 10744-10748 10.1073/pnas.1410415111
26. Rasmussen, S. G. F.; Choi, H. J.; Fung, J. J.; Pardon, E.; Casarosa, P.; Chae, P. S.; DeVree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S.; Schnapp, A.; Konetzki, I.; Sunahara, R. K.; Gellman, S. H.; Pautsch, A.; Steyaert, J.; Weis, W. I.; Kobilka, B. K. Structure of a nanobody-stabilized active state of the beta2 adrenoceptor Nature 2011, 469, 175-180 10.1038/nature09648
27. Rasmussen, S. G. F.; DeVree, B. T.; Zou, Y. Z.; Kruse, A. C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P. S.; Pardon, E.; Calinski, D.; Mathiesen, J. M.; Shah, S. T. A.; Lyons, J. A.; Caffrey, M.; Gellman, S. H.; Steyaert, J.; Skiniotis, G.; Weis, W. I.; Sunahara, R. K.; Kobilka, B. K. Crystal structure of the beta2 adrenergic receptor-Gs protein complex Nature 2011, 477, 549-555 10.1038/nature10361
28. Ring, A. M.; Manglik, A.; Kruse, A. C.; Enos, M. D.; Weis, W. I.; Garcia, K. C.; Kobilka, B. K. Adrenaline-activated structure of beta2-adrenoceptor stabilized by an engineered nanobody Nature 2013, 502, 575-579 10.1038/nature12572
29. Shukla, A. K.; Westfield, G. H.; Xiao, K.; Reis, R. I.; Huang, L. Y.; Tripathi-Shukla, P.; Qian, J.; Li, S.; Blanc, A.; Oleskie, A. N.; Dosey, A. M.; Su, M.; Liang, C. R.; Gu, L. L.; Shan, J. M.; Chen, X.; Hanna, R.; Choi, M.; Yao, X. J.; Klink, B. U.; Kahsai, A. W.; Sidhu, S. S.; Koide, S.; Penczek, P. A.; Kossiakoff, A. A.; Woods, V. L., Jr.; Kobilka, B. K.; Skiniotis, G.; Lefkowitz, R. J. Visualization of arrestin recruitment by a G-protein-coupled receptor Nature 2014, 512, 218-222 10.1038/nature13430
30. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a beta1-adrenergic G-protein-coupled receptor Nature 2008, 454, 486-491 10.1038/nature07101
31. Moukhametzianov, R.; Warne, T.; Edwards, P. C.; Serrano-Vega, M. J.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 8228-8232 10.1073/pnas.1100185108
32. Sato, T.; Baker, J.; Warne, T.; Brown, G. A.; Leslie, A. G.; Congreve, M.; Tate, C. G. Pharmacological analysis and structure determination of 7-methylcyanopindolol-bound beta1-adrenergic receptor Mol. Pharmacol. 2015, 88, 1024-1034 10.1124/mol.115.101030
33. Warne, T.; Moukhametzianov, R.; Baker, J. G.; Nehme, R.; Edwards, P. C.; Leslie, A. G. W.; Schertler, G. F. X.; Tate, C. G. The structural basis for agonist and partial agonist action on a beta1-adrenergic receptor Nature 2011, 469, 241-244 10.1038/nature09746
34. Warne, T.; Edwards, P. C.; Leslie, A. G.; Tate, C. G. Crystal structures of a stabilized beta1-adrenoceptor bound to the biased agonists bucindolol and carvedilol Structure 2012, 20, 841-849 10.1016/j.str.2012.03.014
35. Huang, J.; Chen, S.; Zhang, J. J.; Huang, X. Y. Crystal structure of oligomeric beta1-adrenergic G protein-coupled receptors in ligand-free basal state Nat. Struct. Mol. Biol. 2013, 20, 419-425 10.1038/nsmb.2504
36. Huang, J.; Chen, S.; Zhang, J. J.; Huang, X. Y. Ligand occupancy in crystal structure of beta1-adrenergic G protein-coupled receptor Nat. Struct. Mol. Biol. 2015, 22, 942 10.1038/nsmb.3131
37. Leslie, A. G.; Warne, T.; Tate, C. G. Ligand occupancy in crystal structure of beta1-adrenergic G protein-coupled receptor Nat. Struct. Mol. Biol. 2015, 22, 941-942 10.1038/nsmb.3130
38. Beaulieu, J. M.; Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors Pharmacol. Rev. 2011, 63, 182-217 10.1124/pr.110.002642
39. Missale, C.; Nash, S. R.; Robinson, S. W.; Jaber, M.; Caron, M. G. Dopamine receptors: from structure to function Physiol. Rev. 1998, 78, 189-225
40. Holmes, A.; Lachowicz, J. E.; Sibley, D. R. Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes Neuropharmacology 2004, 47, 1117-1134 10.1016/j.neuropharm.2004.07.034
41. Stemp, G.; Ashmeade, T.; Branch, C. L.; Hadley, M. S.; Hunter, A. J.; Johnson, C. N.; Nash, D. J.; Thewlis, K. M.; Vong, A. K.; Austin, N. E.; Jeffrey, P.; Avenell, K. Y.; Boyfield, I.; Hagan, J. J.; Middlemiss, D. N.; Reavill, C.; Riley, G. J.; Routledge, C.; Wood, M. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat J. Med. Chem. 2000, 43, 1878-1885 10.1021/jm000090i
42. Newman, A. H.; Grundt, P.; Cyriac, G.; Deschamps, J. R.; Taylor, M.; Kumar, R.; Ho, D.; Luedtke, R. R. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists J. Med. Chem. 2009, 52, 2559-2570 10.1021/jm900095y
43. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist Science 2010, 330, 1091-1095 10.1126/science.1197410
44. Heidbreder, C. A.; Newman, A. H. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders Ann. N. Y. Acad. Sci. 2010, 1187, 4-34 10.1111/j.1749-6632.2009.05149.x
45. Boeckler, F.; Gmeiner, P. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects Pharmacol. Ther. 2006, 112, 281-333 10.1016/j.pharmthera.2006.04.007
46. Parsons, M. E.; Ganellin, C. R. Histamine and its receptors Br. J. Pharmacol. 2006, 147, S127-S135 10.1038/sj.bjp.0706440
47. Hill, S. J.; Ganellin, C. R.; Timmerman, H.; Schwartz, J. C.; Shankley, N. P.; Young, J. M.; Schunack, W.; Levi, R.; Haas, H. L. International union of pharmacology. XIII. Classification of histamine receptors Pharmacol. Rev. 1997, 49, 253-278
48. Shimamura, T.; Shiroishi, M.; Weyand, S.; Tsujimoto, H.; Winter, G.; Katritch, V.; Abagyan, R.; Cherezov, V.; Liu, W.; Han, G. W.; Kobayashi, T.; Stevens, R. C.; Iwata, S. Structure of the human histamine H1 receptor complex with doxepin Nature 2011, 475, 65-70 10.1038/nature10236
49. Cusack, B.; Nelson, A.; Richelson, E. Binding of antidepressants to human brain receptors: focus on newer generation compounds Psychopharmacology 1994, 114, 559-565 10.1007/BF02244985
50. Simons, F. E. Advances in H1-antihistamines N. Engl. J. Med. 2004, 351, 2203-2217 10.1056/NEJMra033121
51. Kruse, A. C.; Kobilka, B. K.; Gautam, D.; Sexton, P. M.; Christopoulos, A.; Wess, J. Muscarinic acetylcholine receptors: novel opportunities for drug development Nat. Rev. Drug Discovery 2014, 13, 549-560 10.1038/nrd4295
52. Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Kobayashi, T.; Shiroishi, M.; Zhang, C.; Weis, W. I.; Okada, T.; Kobilka, B. K.; Haga, T.; Kobayashi, T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist Nature 2012, 482, 547-551 10.1038/nature10753
53. Kruse, A. C.; Hu, J. X.; Pan, A. C.; Arlow, D. H.; Rosenbaum, D. M.; Rosemond, E.; Green, H. F.; Liu, T.; Chae, P. S.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Wess, J.; Kobilka, B. K. Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 2012, 482, 552-556 10.1038/nature10867
54. Thal, D. M.; Sun, B.; Feng, D.; Nawaratne, V.; Leach, K.; Felder, C. C.; Bures, M. G.; Evans, D. A.; Weis, W. I.; Bachhawat, P.; Kobilka, T. S.; Sexton, P. M.; Kobilka, B. K.; Christopoulos, A. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors Nature 2016, 531, 335-340 10.1038/nature17188
55. Tautermann, C. S.; Kiechle, T.; Seeliger, D.; Diehl, S.; Wex, E.; Banholzer, R.; Gantner, F.; Pieper, M. P.; Casarosa, P. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor J. Med. Chem. 2013, 56, 8746-8756 10.1021/jm401219y
56. Gregory, K. J.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of muscarinic acetylcholine receptors Curr. Neuropharmacol. 2007, 5, 157-167 10.2174/157015907781695946
57. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hubner, H.; Pardon, E.; Valant, C.; Sexton, P. M.; Christopoulos, A.; Felder, C. C.; Gmeiner, P.; Steyaert, J.; Weis, W. I.; Garcia, K. C.; Wess, J.; Kobilka, B. K. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 2013, 504, 101-106 10.1038/nature12735
58. Nichols, D. E.; Nichols, C. D. Serotonin receptors Chem. Rev. 2008, 108, 1614-1641 10.1021/cr078224o
59. Wang, C.; Jiang, Y.; Ma, J. M.; Wu, H. X.; Wacker, D.; Katritch, V.; Han, G. W.; Liu, W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Gao, X.; Zhou, X. E.; Melcher, K.; Zhang, C. H.; Bai, F.; Yang, H. Y.; Yang, L. L.; Jiang, H. L.; Roth, B. L.; Cherezov, V.; Stevens, R. C.; Xu, H. E. Structural basis for molecular recognition at serotonin receptors Science 2013, 340, 610-614 10.1126/science.1232807
60. Wacker, D.; Wang, C.; Katritch, V.; Han, G. W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Jiang, Y.; Chu, M. H.; Siu, F. Y.; Liu, W.; Xu, H. E.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Structural features for functional selectivity at serotonin receptors Science 2013, 340, 615-619 10.1126/science.1232808
61. Liu, W.; Wacker, D.; Gati, C.; Han, G. W.; James, D.; Wang, D.; Nelson, G.; Weierstall, U.; Katritch, V.; Barty, A.; Zatsepin, N. A.; Li, D.; Messerschmidt, M.; Boutet, S.; Williams, G. J.; Koglin, J. E.; Seibert, M. M.; Wang, C.; Shah, S. T.; Basu, S.; Fromme, R.; Kupitz, C.; Rendek, K. N.; Grotjohann, I.; Fromme, P.; Kirian, R. A.; Beyerlein, K. R.; White, T. A.; Chapman, H. N.; Caffrey, M.; Spence, J. C.; Stevens, R. C.; Cherezov, V. Serial femtosecond crystallography of G protein-coupled receptors Science 2013, 342, 1521-1524 10.1126/science.1244142
62. Kaebisch, C.; Schipper, D.; Babczyk, P.; Tobiasch, E. The role of purinergic receptors in stem cell differentiation Comput. Struct. Biotechnol. J. 2015, 13, 75-84 10.1016/j.csbj.2014.11.003
63. Dunwiddie, T. V.; Masino, S. A. The role and regulation of adenosine in the central nervous system Annu. Rev. Neurosci. 2001, 24, 31-55 10.1146/annurev.neuro.24.1.31
64. Dore, A. S.; Robertson, N.; Errey, J. C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.; Magnani, F.; Tate, C. G.; Weir, M.; Marshall, F. H. Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine Structure 2011, 19, 1283-1293 10.1016/j.str.2011.06.014
65. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist Science 2008, 322, 1211-1217 10.1126/science.1164772
66. Hino, T.; Arakawa, T.; Iwanari, H.; Yurugi-Kobayashi, T.; Ikeda-Suno, C.; Nakada-Nakura, Y.; Kusano-Arai, O.; Weyand, S.; Shimamura, T.; Nomura, N.; Cameron, A. D.; Kobayashi, T.; Hamakubo, T.; Iwata, S.; Murata, T. G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody Nature 2012, 482, 237-240 10.1038/nature10750
67. Batyuk, A.; Galli, L.; Ishchenko, A.; Han, G. W.; Gati, C.; Popov, P. A.; Lee, M. Y.; Stauch, B.; White, T. A.; Barty, A.; Aquila, A.; Hunter, M. S.; Liang, M.; Boutet, S.; Pu, M.; Liu, Z. J.; Nelson, G.; James, D.; Li, C.; Zhao, Y.; Spence, J. C.; Liu, W.; Fromme, P.; Katritch, V.; Weierstall, U.; Stevens, R. C.; Cherezov, V. Native phasing of x-ray free-electron laser data for a G protein-coupled receptor Sci. Adv. 2016, 2, e1600292 10.1126/sciadv.1600292
68. Segala, E.; Guo, D.; Cheng, R. K.; Bortolato, A.; Deflorian, F.; Dore, A. S.; Errey, J. C.; Heitman, L. H.; AP, I. J.; Marshall, F. H.; Cooke, R. M. Controlling the dissociation of ligands from the adenosine A2A receptor through modulation of salt bridge strength J. Med. Chem. 2016, 59, 6470-6479 10.1021/acs.jmedchem.6b00653
69. Congreve, M.; Andrews, S. P.; Dore, A. S.; Hollenstein, K.; Hurrell, E.; Langmead, C. J.; Mason, J. S.; Ng, I. W.; Tehan, B.; Zhukov, A.; Weir, M.; Marshall, F. H. Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design J. Med. Chem. 2012, 55, 1898-1903 10.1021/jm201376w
70. Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G.; Tate, C. G. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation Nature 2011, 474, 521-525 10.1038/nature10136
71. Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao, Z. G.; Cherezov, V.; Stevens, R. C. Structure of an agonist-bound human A2A adenosine receptor Science 2011, 332, 322-327 10.1126/science.1202793
72. Lebon, G.; Edwards, P. C.; Leslie, A. G.; Tate, C. G. Molecular determinants of CGS21680 binding to the human adenosine A2A receptor Mol. Pharmacol. 2015, 87, 907-915 10.1124/mol.114.097360
73. Huang, W.; Manglik, A.; Venkatakrishnan, A. J.; Laeremans, T.; Feinberg, E. N.; Sanborn, A. L.; Kato, H. E.; Livingston, K. E.; Thorsen, T. S.; Kling, R. C.; Granier, S.; Gmeiner, P.; Husbands, S. M.; Traynor, J. R.; Weis, W. I.; Steyaert, J.; Dror, R. O.; Kobilka, B. K. Structural insights into micro-opioid receptor activation Nature 2015, 524, 315-321 10.1038/nature14886
74. Lebon, G.; Warne, T.; Tate, C. G. Agonist-bound structures of G protein-coupled receptors Curr. Opin. Struct. Biol. 2012, 22, 482-490 10.1016/j.sbi.2012.03.007
75. Carpenter, B.; Nehme, R.; Warne, T.; Leslie, A. G.; Tate, C. G. Structure of the adenosine A2A receptor bound to an engineered G protein Nature 2016, 536, 104-107 10.1038/nature18966
76. Tate, C. G.; Schertler, G. F. Engineering G protein-coupled receptors to facilitate their structure determination Curr. Opin. Struct. Biol. 2009, 19, 386-395 10.1016/j.sbi.2009.07.004
77. Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Roth, C. B.; Heitman, L. H.; AP, I. J.; Cherezov, V.; Stevens, R. C. Structural basis for allosteric regulation of GPCRs by sodium ions Science 2012, 337, 232-236 10.1126/science.1219218
78. Zhang, C.; Srinivasan, Y.; Arlow, D. H.; Fung, J. J.; Palmer, D.; Zheng, Y.; Green, H. F.; Pandey, A.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Coughlin, S. R.; Kobilka, B. K. High-resolution crystal structure of human protease-activated receptor 1 Nature 2012, 492, 387-392 10.1038/nature11701
79. Fenalti, G.; Giguere, P. M.; Katritch, V.; Huang, X. P.; Thompson, A. A.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Molecular control of delta-opioid receptor signalling Nature 2014, 506, 191-196 10.1038/nature12944
80. Miller-Gallacher, J. L.; Nehme, R.; Warne, T.; Edwards, P. C.; Schertler, G. F.; Leslie, A. G.; Tate, C. G. The 2.1 A resolution structure of cyanopindolol-bound beta1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor PLoS One 2014, 9, e92727 10.1371/journal.pone.0092727
81. Zhang, D.; Gao, Z. G.; Zhang, K.; Kiselev, E.; Crane, S.; Wang, J.; Paoletta, S.; Yi, C.; Ma, L.; Zhang, W.; Han, G. W.; Liu, H.; Cherezov, V.; Katritch, V.; Jiang, H.; Stevens, R. C.; Jacobson, K. A.; Zhao, Q.; Wu, B. Two disparate ligand-binding sites in the human P2Y1 receptor Nature 2015, 520, 317-321 10.1038/nature14287
82. Zhang, K.; Zhang, J.; Gao, Z. G.; Zhang, D.; Zhu, L.; Han, G. W.; Moss, S. M.; Paoletta, S.; Kiselev, E.; Lu, W.; Fenalti, G.; Zhang, W.; Muller, C. E.; Yang, H.; Jiang, H.; Cherezov, V.; Katritch, V.; Jacobson, K. A.; Stevens, R. C.; Wu, B.; Zhao, Q. Structure of the human P2Y12 receptor in complex with an antithrombotic drug Nature 2014, 509, 115-118 10.1038/nature13083
83. Zhang, J.; Zhang, K.; Gao, Z. G.; Paoletta, S.; Zhang, D.; Han, G. W.; Li, T.; Ma, L.; Zhang, W.; Muller, C. E.; Yang, H.; Jiang, H.; Cherezov, V.; Katritch, V.; Jacobson, K. A.; Stevens, R. C.; Wu, B.; Zhao, Q. Agonist-bound structure of the human P2Y12 receptor Nature 2014, 509, 119-122 10.1038/nature13288
84. Jin, J.; Kunapuli, S. P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 8070-8074 10.1073/pnas.95.14.8070
85. Jacobson, K. A.; Deflorian, F.; Mishra, S.; Costanzi, S. Pharmacochemistry of the platelet purinergic receptors Purinergic Signalling 2011, 7, 305-324 10.1007/s11302-011-9216-0
86. Schmidt, P.; Ritscher, L.; Dong, E. N.; Hermsdorf, T.; Coster, M.; Wittkopf, D.; Meiler, J.; Schoneberg, T. Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12 Mol. Pharmacol. 2013, 83, 256-266 10.1124/mol.112.082198
87. Bach, P.; Antonsson, T.; Bylund, R.; Bjorkman, J. A.; Osterlund, K.; Giordanetto, F.; van Giezen, J. J.; Andersen, S. M.; Zachrisson, H.; Zetterberg, F. Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283 J. Med. Chem. 2013, 56, 7015-7024 10.1021/jm400820m
88. Kalantzi, K. I.; Tsoumani, M. E.; Goudevenos, I. A.; Tselepis, A. D. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives Expert Rev. Clin. Pharmacol. 2012, 5, 319-336 10.1586/ecp.12.19
89. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 2010, 330, 1066-1071 10.1126/science.1194396
90. Qin, L.; Kufareva, I.; Holden, L. G.; Wang, C.; Zheng, Y.; Zhao, C.; Fenalti, G.; Wu, H.; Han, G. W.; Cherezov, V.; Abagyan, R.; Stevens, R. C.; Handel, T. M. Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine Science 2015, 347, 1117-1122 10.1126/science.1261064
91. Thompson, A. A.; Liu, W.; Chun, E.; Katritch, V.; Wu, H.; Vardy, E.; Huang, X. P.; Trapella, C.; Guerrini, R.; Calo, G.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic Nature 2012, 485, 395-399 10.1038/nature11085
92. White, J. F.; Noinaj, N.; Shibata, Y.; Love, J.; Kloss, B.; Xu, F.; Gvozdenovic-Jeremic, J.; Shah, P.; Shiloach, J.; Tate, C. G.; Grisshammer, R. Structure of the agonist-bound neurotensin receptor Nature 2012, 490, 508-513 10.1038/nature11558
93. Shihoya, W.; Nishizawa, T.; Okuta, A.; Tani, K.; Dohmae, N.; Fujiyoshi, Y.; Nureki, O.; Doi, T. Activation mechanism of endothelin ETB receptor by endothelin-1 Nature 2016, 537, 363-368 10.1038/nature19319
94. Rajagopalan, L.; Rajarathnam, K. Structural basis of chemokine receptor function - a model for binding affinity and ligand selectivity Biosci. Rep. 2006, 26, 325-339 10.1007/s10540-006-9025-9
95. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G. W.; Kufareva, I.; Li, T.; Ma, L.; Fenalti, G.; Zhang, W.; Xie, X.; Yang, H.; Jiang, H.; Cherezov, V.; Liu, H.; Stevens, R. C.; Zhao, Q.; Wu, B. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex Science 2013, 341, 1387-1390 10.1126/science.1241475
96. Debnath, B.; Xu, S.; Grande, F.; Garofalo, A.; Neamati, N. Small molecule inhibitors of CXCR4 Theranostics 2013, 3, 47-75 10.7150/thno.5376
97. Shiraishi, M.; Aramaki, Y.; Seto, M.; Imoto, H.; Nishikawa, Y.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Nishimura, O.; Baba, M.; Fujino, M. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety J. Med. Chem. 2000, 43, 2049-2063 10.1021/jm9906264
98. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 2005, 49, 4721-4732 10.1128/AAC.49.11.4721-4732.2005
99. Pasternak, G. W. Opioids and their receptors: are we there yet? Neuropharmacology 2014, 76 Pt B, 198-203 10.1016/j.neuropharm.2013.03.039
100. Shonberg, J.; Kling, R. C.; Gmeiner, P.; Lober, S. GPCR crystal structures: medicinal chemistry in the pocket Bioorg. Med. Chem. 2015, 23, 3880-3906 10.1016/j.bmc.2014.12.034
101. Fenalti, G.; Zatsepin, N. A.; Betti, C.; Giguere, P.; Han, G. W.; Ishchenko, A.; Liu, W.; Guillemyn, K.; Zhang, H.; James, D.; Wang, D.; Weierstall, U.; Spence, J. C. H.; Boutet, S.; Messerschmidt, M.; Williams, G. J.; Gati, C.; Yefanov, O. M.; White, T. A.; Oberthuer, D.; Metz, M.; Yoon, C. H.; Barty, A.; Chapman, H. N.; Basu, S.; Coe, J.; Conrad, C. E.; Fromme, R.; Fromme, P.; Tourwe, D.; Schiller, P. W.; Roth, B. L.; Ballet, S.; Katritch, V.; Stevens, R. C.; Cherezov, V. Structural basis for bifunctional peptide recognition at human delta-opioid receptor Nat. Struct. Mol. Biol. 2015, 22, 265-268 10.1038/nsmb.2965
102. O'Connor, C.; White, K. L.; Doncescu, N.; Didenko, T.; Roth, B. L.; Czaplicki, G.; Stevens, R. C.; Wuthrich, K.; Milon, A. NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 11852-11857 10.1073/pnas.1510117112
103. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist Nature 2012, 485, 321-326 10.1038/nature10954
104. Granier, S.; Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Weis, W. I.; Kobilka, B. K. Structure of the delta-opioid receptor bound to naltrindole Nature 2012, 485, 400-404 10.1038/nature11111
105. Costa, T.; Lang, J.; Gless, C.; Herz, A. Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions Mol. Pharmacol. 1990, 37, 383-394
106. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa-opioid receptor in complex with JDTic Nature 2012, 485, 327-332 10.1038/nature10939
107. Yan, F.; Bikbulatov, R. V.; Mocanu, V.; Dicheva, N.; Parker, C. E.; Wetsel, W. C.; Mosier, P. D.; Westkaemper, R. B.; Allen, J. A.; Zjawiony, J. K.; Roth, B. L. Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor Biochemistry 2009, 48, 6898-6908 10.1021/bi900605n
108. Miller, R. L.; Thompson, A. A.; Trapella, C.; Guerrini, R.; Malfacini, D.; Patel, N.; Han, G. W.; Cherezov, V.; Calo, G.; Katritch, V.; Stevens, R. C. The importance of ligand-receptor conformational pairs in stabilization: spotlight on the N/OFQ G protein-coupled receptor Structure 2015, 23, 2291-2299 10.1016/j.str.2015.07.024
109. Egloff, P.; Hillenbrand, M.; Klenk, C.; Batyuk, A.; Heine, P.; Balada, S.; Schlinkmann, K. M.; Scott, D. J.; Schutz, M.; Pluckthun, A. Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli Proc. Natl. Acad. Sci. U. S. A. 2014, 111, E655-E662 10.1073/pnas.1317903111
110. Luca, S.; White, J. F.; Sohal, A. K.; Filippov, D. V.; van Boom, J. H.; Grisshammer, R.; Baldus, M. The conformation of neurotensin bound to its G protein-coupled receptor Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 10706-10711 10.1073/pnas.1834523100
111. Krumm, B. E.; White, J. F.; Shah, P.; Grisshammer, R. Structural prerequisites for G-protein activation by the neurotensin receptor Nat. Commun. 2015, 6, 7895 10.1038/ncomms8895
112. Ahn, H. S.; Arik, L.; Boykow, G.; Burnett, D. A.; Caplen, M. A.; Czarniecki, M.; Domalski, M. S.; Foster, C.; Manna, M.; Stamford, A. W.; Wu, Y. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists Bioorg. Med. Chem. Lett. 1999, 9, 2073-2078 10.1016/S0960-894X(99)00339-X
113. Chackalamannil, S.; Xia, Y.; Greenlee, W. J.; Clasby, M.; Doller, D.; Tsai, H.; Asberom, T.; Czarniecki, M.; Ahn, H. S.; Boykow, G.; Foster, C.; Agans-Fantuzzi, J.; Bryant, M.; Lau, J.; Chintala, M. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents J. Med. Chem. 2005, 48, 5884-5887 10.1021/jm0502236
114. FDA approves Zontivity to reduce the risk of heart attacks and stroke. https://www.drugs.com/newdrugs/fda-approves-zontivity-reduce-risk-heart-attacks-stroke-4039.html (accessed Mar 21, 2017).
115. Zhang, H.; Unal, H.; Gati, C.; Han, G. W.; Liu, W.; Zatsepin, N. A.; James, D.; Wang, D.; Nelson, G.; Weierstall, U.; Sawaya, M. R.; Xu, Q.; Messerschmidt, M.; Williams, G. J.; Boutet, S.; Yefanov, O. M.; White, T. A.; Wang, C.; Ishchenko, A.; Tirupula, K. C.; Desnoyer, R.; Coe, J.; Conrad, C. E.; Fromme, P.; Stevens, R. C.; Katritch, V.; Karnik, S. S.; Cherezov, V. Structure of the angiotensin receptor revealed by serial femtosecond crystallography Cell 2015, 161, 833-844 10.1016/j.cell.2015.04.011
116. Michelson, D.; Snyder, E.; Paradis, E.; Chengan-Liu, M.; Snavely, D. B.; Hutzelmann, J.; Walsh, J. K.; Krystal, A. D.; Benca, R. M.; Cohn, M.; Lines, C.; Roth, T.; Herring, W. J. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial Lancet Neurol. 2014, 13, 461-471 10.1016/S1474-4422(14)70053-5
117. Yin, J.; Mobarec, J. C.; Kolb, P.; Rosenbaum, D. M. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant Nature 2015, 519, 247-250 10.1038/nature14035
118. Yin, J.; Babaoglu, K.; Brautigam, C. A.; Clark, L.; Shao, Z.; Scheuermann, T. H.; Harrell, C. M.; Gotter, A. L.; Roecker, A. J.; Winrow, C. J.; Renger, J. J.; Coleman, P. J.; Rosenbaum, D. M. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors Nat. Struct. Mol. Biol. 2016, 23, 293-299 10.1038/nsmb.3183
119. Kedzierski, R. M.; Yanagisawa, M. Endothelin system: the double-edged sword in health and disease Annu. Rev. Pharmacol. Toxicol. 2001, 41, 851-876 10.1146/annurev.pharmtox.41.1.851
120. Kohan, D. E.; Rossi, N. F.; Inscho, E. W.; Pollock, D. M. Regulation of blood pressure and salt homeostasis by endothelin Physiol. Rev. 2011, 91, 1-77 10.1152/physrev.00060.2009
121. Davenport, A. P. International union of pharmacology. XXIX. Update on endothelin receptor nomenclature Pharmacol. Rev. 2002, 54, 219-226 10.1124/pr.54.2.219
122. Maguire, J. J.; Davenport, A. P. Endothelin@25-new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR review 12 Br. J. Pharmacol. 2014, 171, 5555-5572 10.1111/bph.12874
123. Briyal, S.; Nguyen, C.; Leonard, M.; Gulati, A. Stimulation of endothelin B receptors by IRL-1620 decreases the progression of Alzheimer's disease Neuroscience 2015, 301, 1-11 10.1016/j.neuroscience.2015.05.044
124. Janes, R. W.; Peapus, D. H.; Wallace, B. A. The crystal structure of human endothelin Nat. Struct. Mol. Biol. 1994, 1, 311-319 10.1038/nsb0594-311
125. Takashima, H.; Mimura, N.; Ohkubo, T.; Yoshida, T.; Tamaoki, H.; Kobayashi, Y. Distributed computing and NMR constraint-based high-resolution structure determination: applied for bioactive Peptide endothelin-1 to determine C-terminal folding J. Am. Chem. Soc. 2004, 126, 4504-4505 10.1021/ja031637w
126. Andersen, N. H.; Chen, C. P.; Marschner, T. M.; Krystek, S. R., Jr.; Bassolino, D. A. Conformational isomerism of endothelin in acidic aqueous media: a quantitative NOESY analysis Biochemistry 1992, 31, 1280-1295 10.1021/bi00120a003
127. Houthuijzen, J. M.; Daenen, L. G.; Roodhart, J. M.; Oosterom, I.; van Jaarsveld, M. T.; Govaert, K. M.; Smith, M. E.; Sadatmand, S. J.; Rosing, H.; Kruse, F.; Helms, B. J.; van Rooijen, N.; Beijnen, J. H.; Haribabu, B.; van de Lest, C. H.; Voest, E. E. Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response Nat. Commun. 2014, 5, 1-10 10.1038/ncomms6275
128. van Jaarsveld, M. T.; Houthuijzen, J. M.; Voest, E. E. Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer Oncogene 2016, 35, 4021-4035 10.1038/onc.2015.467
129. Hanson, M. A.; Roth, C. B.; Jo, E.; Griffith, M. T.; Scott, F. L.; Reinhart, G.; Desale, H.; Clemons, B.; Cahalan, S. M.; Schuerer, S. C.; Sanna, M. G.; Han, G. W.; Kuhn, P.; Rosen, H.; Stevens, R. C. Crystal structure of a lipid G protein-coupled receptor Science 2012, 335, 851-855 10.1126/science.1215904
130. Chrencik, J. E.; Roth, C. B.; Terakado, M.; Kurata, H.; Omi, R.; Kihara, Y.; Warshaviak, D.; Nakade, S.; Asmar-Rovira, G.; Mileni, M.; Mizuno, H.; Griffith, M. T.; Rodgers, C.; Han, G. W.; Velasquez, J.; Chun, J.; Stevens, R. C.; Hanson, M. A. Crystal structure of antagonist bound human lysophosphatidic acid receptor 1 Cell 2015, 161, 1633-1643 10.1016/j.cell.2015.06.002
131. Srivastava, A.; Yano, J.; Hirozane, Y.; Kefala, G.; Gruswitz, F.; Snell, G.; Lane, W.; Ivetac, A.; Aertgeerts, K.; Nguyen, J.; Jennings, A.; Okada, K. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 Nature 2014, 513, 124-127 10.1038/nature13494
132. Rivera, R.; Chun, J. Biological effects of lysophospholipids Rev. Physiol., Biochem. Pharmacol. 2006, 160, 25-46 10.1007/112-0507
133. Chun, J.; Goetzl, E. J.; Hla, T.; Igarashi, Y.; Lynch, K. R.; Moolenaar, W.; Pyne, S.; Tigyi, G. International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature Pharmacol. Rev. 2002, 54, 265-269 10.1124/pr.54.2.265
134. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat. Rev. Drug Discovery 2010, 9, 883-897 10.1038/nrd3248
135. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist ACS Med. Chem. Lett. 2010, 1, 290-294 10.1021/ml1000855
136. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D.; Ferrara, P.; Soubrié, P.; Brelière, J. C.; Le Fur, G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 1994, 350, 240-244 10.1016/0014-5793(94)00773-X
137. Janero, D. R.; Makriyannis, A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Emerging Drugs 2009, 14, 43-65 10.1517/14728210902736568
138. Hua, T.; Vemuri, K.; Pu, M.; Qu, L.; Han, G. W.; Wu, Y.; Zhao, S.; Shui, W.; Li, S.; Korde, A.; Laprairie, R. B.; Stahl, E. L.; Ho, J. H.; Zvonok, N.; Zhou, H.; Kufareva, I.; Wu, B.; Zhao, Q.; Hanson, M. A.; Bohn, L. M.; Makriyannis, A.; Stevens, R. C.; Liu, Z. J. Crystal structure of the human cannabinoid receptor CB1 Cell 2016, 167, 750-762 10.1016/j.cell.2016.10.004
139. Nygaard, R.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Schwartz, T. W. Ligand binding and micro-switches in 7TM receptor structures Trends Pharmacol. Sci. 2009, 30, 249-259 10.1016/j.tips.2009.02.006
140. Kobilka, B. K. G protein coupled receptor structure and activation Biochim. Biophys. Acta, Biomembr. 2007, 1768, 794-807 10.1016/j.bbamem.2006.10.021
141. Choe, H. W.; Park, J. H.; Kim, Y. J.; Ernst, O. P. Transmembrane signaling by GPCRs: insight from rhodopsin and opsin structures Neuropharmacology 2011, 60, 52-57 10.1016/j.neuropharm.2010.07.018
142. Katritch, V.; Cherezov, V.; Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily Annu. Rev. Pharmacol. Toxicol. 2013, 53, 531-556 10.1146/annurev-pharmtox-032112-135923
143. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Heydenreich, F. M.; Flock, T.; Miljus, T.; Balaji, S.; Bouvier, M.; Veprintsev, D. B.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region Nature 2016, 536, 484-487 10.1038/nature19107
144. Scheerer, P.; Park, J. H.; Hildebrand, P. W.; Kim, Y. J.; Krauss, N.; Choe, H. W.; Hofmann, K. P.; Ernst, O. P. Crystal structure of opsin in its G-protein-interacting conformation Nature 2008, 455, 497-502 10.1038/nature07330
145. Kang, Y.; Zhou, X. E.; Gao, X.; He, Y.; Liu, W.; Ishchenko, A.; Barty, A.; White, T. A.; Yefanov, O.; Han, G. W.; Xu, Q.; de Waal, P. W.; Ke, J.; Tan, M. H.; Zhang, C.; Moeller, A.; West, G. M.; Pascal, B. D.; Van Eps, N.; Caro, L. N.; Vishnivetskiy, S. A.; Lee, R. J.; Suino-Powell, K. M.; Gu, X.; Pal, K.; Ma, J.; Zhi, X.; Boutet, S.; Williams, G. J.; Messerschmidt, M.; Gati, C.; Zatsepin, N. A.; Wang, D.; James, D.; Basu, S.; Roy-Chowdhury, S.; Conrad, C. E.; Coe, J.; Liu, H.; Lisova, S.; Kupitz, C.; Grotjohann, I.; Fromme, R.; Jiang, Y.; Tan, M.; Yang, H.; Li, J.; Wang, M.; Zheng, Z.; Li, D.; Howe, N.; Zhao, Y.; Standfuss, J.; Diederichs, K.; Dong, Y.; Potter, C. S.; Carragher, B.; Caffrey, M.; Jiang, H.; Chapman, H. N.; Spence, J. C.; Fromme, P.; Weierstall, U.; Ernst, O. P.; Katritch, V.; Gurevich, V. V.; Griffin, P. R.; Hubbell, W. L.; Stevens, R. C.; Cherezov, V.; Melcher, K.; Xu, H. E. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser Nature 2015, 523, 561-567 10.1038/nature14656
146. Katritch, V.; Fenalti, G.; Abola, E. E.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Allosteric sodium in class A GPCR signaling Trends Biochem. Sci. 2014, 39, 233-244 10.1016/j.tibs.2014.03.002
147. Pert, C. B.; Pasternak, G.; Snyder, S. H. Opiate agonists and antagonists discriminated by receptor binding in brain Science 1973, 182, 1359-1361 10.1126/science.182.4119.1359
148. Gutierrez-de-Teran, H.; Massink, A.; Rodriguez, D.; Liu, W.; Han, G. W.; Joseph, J. S.; Katritch, I.; Heitman, L. H.; Xia, L.; Ijzerman, A. P.; Cherezov, V.; Katritch, V.; Stevens, R. C. The role of a sodium ion binding site in the allosteric modulation of the A2A adenosine G protein-coupled receptor Structure 2013, 21, 2175-2185 10.1016/j.str.2013.09.020
149. Ranganathan, A.; Dror, R. O.; Carlsson, J. Insights into the role of Asp79(2.50) in beta2 adrenergic receptor activation from molecular dynamics simulations Biochemistry 2014, 53, 7283-7296 10.1021/bi5008723
150. Selent, J.; Sanz, F.; Pastor, M.; De Fabritiis, G. Induced effects of sodium ions on dopaminergic G-protein coupled receptors PLoS Comput. Biol. 2010, 6, 1-6 10.1371/journal.pcbi.1000884
151. Yuan, S.; Vogel, H.; Filipek, S. The role of water and sodium ions in the activation of the mu-opioid receptor Angew. Chem., Int. Ed. 2013, 52, 10112-10115 10.1002/anie.201302244
152. Shang, Y.; LeRouzic, V.; Schneider, S.; Bisignano, P.; Pasternak, G. W.; Filizola, M. Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions Biochemistry 2014, 53, 5140-5149 10.1021/bi5006915
153. Miao, Y.; Caliman, A. D.; McCammon, J. A. Allosteric effects of sodium ion binding on activation of the m3 muscarinic G-protein-coupled receptor Biophys. J. 2015, 108, 1796-1806 10.1016/j.bpj.2015.03.003
154. Devi, L. A. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking Trends Pharmacol. Sci. 2001, 22, 532-537 10.1016/S0165-6147(00)01799-5
155. Salom, D.; Lodowski, D. T.; Stenkamp, R. E.; Le Trong, I.; Golczak, M.; Jastrzebska, B.; Harris, T.; Ballesteros, J. A.; Palczewski, K. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 16123-16128 10.1073/pnas.0608022103
156. Liang, Y.; Fotiadis, D.; Filipek, S.; Saperstein, D. A.; Palczewski, K.; Engel, A. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes J. Biol. Chem. 2003, 278, 21655-21662 10.1074/jbc.M302536200
157. Ferre, S.; Casado, V.; Devi, L. A.; Filizola, M.; Jockers, R.; Lohse, M. J.; Milligan, G.; Pin, J. P.; Guitart, X. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives Pharmacol. Rev. 2014, 66, 413-434 10.1124/pr.113.008052
158. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular signatures of G-protein-coupled receptors Nature 2013, 494, 185-194 10.1038/nature11896
159. Rahmeh, R.; Damian, M.; Cottet, M.; Orcel, H.; Mendre, C.; Durroux, T.; Sharma, K. S.; Durand, G.; Pucci, B.; Trinquet, E.; Zwier, J. M.; Deupi, X.; Bron, P.; Baneres, J. L.; Mouillac, B.; Granier, S. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 6733-6738 10.1073/pnas.1201093109
160. Corbisier, J.; Gales, C.; Huszagh, A.; Parmentier, M.; Springael, J. Y. Biased signaling at chemokine receptors J. Biol. Chem. 2015, 290, 9542-9554 10.1074/jbc.M114.596098
161. Lefkowitz, R. J. Historical review: a brief history and personal retrospective of seven-transmembrane receptors Trends Pharmacol. Sci. 2004, 25, 413-422 10.1016/j.tips.2004.06.006
162. Wisler, J. W.; Xiao, K.; Thomsen, A. R.; Lefkowitz, R. J. Recent developments in biased agonism Curr. Opin. Cell Biol. 2014, 27, 18-24 10.1016/j.ceb.2013.10.008
163. Violin, J. D.; Crombie, A. L.; Soergel, D. G.; Lark, M. W. Biased ligands at G-protein-coupled receptors: promise and progress Trends Pharmacol. Sci. 2014, 35, 308-316 10.1016/j.tips.2014.04.007
164. Kenakin, T.; Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discovery 2013, 12, 205-216 10.1038/nrd3954
165. Quoyer, J.; Janz, J. M.; Luo, J.; Ren, Y.; Armando, S.; Lukashova, V.; Benovic, J. L.; Carlson, K. E.; Hunt, S. W., 3rd; Bouvier, M. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein Proc. Natl. Acad. Sci. U. S. A. 2013, 110, E5088-E5097 10.1073/pnas.1312515110
166. Staus, D. P.; Wingler, L. M.; Strachan, R. T.; Rasmussen, S. G.; Pardon, E.; Ahn, S.; Steyaert, J.; Kobilka, B. K.; Lefkowitz, R. J. Regulation of beta2-adrenergic receptor function by conformationally selective single-domain intrabodies Mol. Pharmacol. 2014, 85, 472-481 10.1124/mol.113.089516
167. Shukla, A. K. Biasing GPCR signaling from inside Sci. Signaling 2014, 7, pe3 10.1126/scisignal.2005021
168. Shukla, A. K.; Singh, G.; Ghosh, E. Emerging structural insights into biased GPCR signaling Trends Biochem. Sci. 2014, 39, 594-602 10.1016/j.tibs.2014.10.001
169. Shukla, A. K.; Xiao, K.; Lefkowitz, R. J. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling Trends Biochem. Sci. 2011, 36, 457-469 10.1016/j.tibs.2011.06.003
170. Correll, C. C.; McKittrick, B. A. Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery J. Med. Chem. 2014, 57, 6887-6896 10.1021/jm401677g
171. Khoury, E.; Clement, S.; Laporte, S. A. Allosteric and biased G protein-coupled receptor signaling regulation: potentials for new therapeutics Front. Endocrinol. 2014, 5, 68 10.3389/fendo.2014.00068
172. Staus, D. P.; Strachan, R. T.; Manglik, A.; Pani, B.; Kahsai, A. W.; Kim, T. H.; Wingler, L. M.; Ahn, S.; Chatterjee, A.; Masoudi, A.; Kruse, A. C.; Pardon, E.; Steyaert, J.; Weis, W. I.; Prosser, R. S.; Kobilka, B. K.; Costa, T.; Lefkowitz, R. J. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation Nature 2016, 535, 448-452 10.1038/nature18636
173. Andrews, S. P.; Brown, G. A.; Christopher, J. A. Structure-based and fragment-based GPCR drug discovery ChemMedChem 2014, 9, 256-275 10.1002/cmdc.201300382
174. Cavasotto, C. N.; Palomba, D. Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models Chem. Commun. 2015, 51, 13576-13594 10.1039/C5CC05050B
175. Vyas, V. K.; Ukawala, R. D.; Ghate, M.; Chintha, C. Homology modeling a fast tool for drug discovery: current perspectives Indian J. Pharm. Sci. 2012, 74, 1-17 10.4103/0250-474X.102537
176. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor Science 2000, 289, 739-745 10.1126/science.289.5480.739
177. Ngo, T.; Kufareva, I.; Coleman, J. L. J.; Graham, R. M.; Abagyan, R.; Smith, N. J. Identifying ligands at orphan GPCRs: current status using structure-based approaches Br. J. Pharmacol. 2016, 173, 2934-2951 10.1111/bph.13452
178. Ferreira, L. G.; dos Santos, R. N.; Oliva, G.; Andricopulo, A. D. Molecular docking and structure-based drug design strategies Molecules 2015, 20, 13384-13421 10.3390/molecules200713384
179. Huang, S. Y.; Zou, X. Advances and challenges in protein-ligand docking Int. J. Mol. Sci. 2010, 11, 3016-3034 10.3390/ijms11083016
180. Kumari, P.; Ghosh, E.; Shukla, A. K. Emerging approaches to GPCR ligand screening for drug discovery Trends Mol. Med. 2015, 21, 687-701 10.1016/j.molmed.2015.09.002
181. Sabio, M.; Jones, K.; Topiol, S. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds Bioorg. Med. Chem. Lett. 2008, 18, 5391-5395 10.1016/j.bmcl.2008.09.046
182. Kolb, P.; Rosenbaum, D. M.; Irwin, J. J.; Fung, J. J.; Kobilka, B. K.; Shoichet, B. K. Structure-based discovery of beta2-adrenergic receptor ligands Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 6843-6848 10.1073/pnas.0812657106
183. Katritch, V.; Jaakola, V. P.; Lane, J. R.; Lin, J.; Ijzerman, A. P.; Yeager, M.; Kufareva, I.; Stevens, R. C.; Abagyan, R. Structure-based discovery of novel chemotypes for adenosine A2A receptor antagonists J. Med. Chem. 2010, 53, 1799-809 10.1021/jm901647p
184. Carlsson, J.; Yoo, L.; Gao, Z. G.; Irwin, J. J.; Shoichet, B. K.; Jacobson, K. A. Structure-based discovery of A2A adenosine receptor ligands J. Med. Chem. 2010, 53, 3748-3755 10.1021/jm100240h
185. Kim, J.; Wess, J.; van Rhee, A. M.; Schoneberg, T.; Jacobson, K. A. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor J. Biol. Chem. 1995, 270, 13987-13997 10.1074/jbc.270.23.13987
186. Langmead, C. J.; Andrews, S. P.; Congreve, M.; Errey, J. C.; Hurrell, E.; Marshall, F. H.; Mason, J. S.; Richardson, C. M.; Robertson, N.; Zhukov, A.; Weir, M. Identification of novel adenosine A2A receptor antagonists by virtual screening J. Med. Chem. 2012, 55, 1904-1909 10.1021/jm201455y
187. Jazayeri, A.; Andrews, S. P.; Marshall, F. H. Structurally enabled discovery of adenosine A2A receptor antagonists Chem. Rev. 2017, 117, 21-37 10.1021/acs.chemrev.6b00119
188. Agelis, G.; Resvani, A.; Koukoulitsa, C.; Tumova, T.; Slaninova, J.; Kalavrizioti, D.; Spyridaki, K.; Afantitis, A.; Melagraki, G.; Siafaka, A.; Gkini, E.; Megariotis, G.; Grdadolnik, S. G.; Papadopoulos, M. G.; Vlahakos, D.; Maragoudakis, M.; Liapakis, G.; Mavromoustakos, T.; Matsoukas, J. Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers Eur. J. Med. Chem. 2013, 62, 352-370 10.1016/j.ejmech.2012.12.044
189. Negri, A.; Rives, M. L.; Caspers, M. J.; Prisinzano, T. E.; Javitch, J. A.; Filizola, M. Discovery of a novel selective kappa-opioid receptor agonist using crystal structure-based virtual screening J. Chem. Inf. Model. 2013, 53, 521-526 10.1021/ci400019t
190. Katritch, V.; Kufareva, I.; Abagyan, R. Structure based prediction of subtype-selectivity for adenosine receptor antagonists Neuropharmacology 2011, 60, 108-115 10.1016/j.neuropharm.2010.07.009
191. Kolb, P.; Phan, K.; Gao, Z. G.; Marko, A. C.; Sali, A.; Jacobson, K. A. Limits of ligand selectivity from docking to models: in silico screening for A1 adenosine receptor antagonists PLoS One 2012, 7, e49910 10.1371/journal.pone.0049910
192. Kruse, A. C.; Weiss, D. R.; Rossi, M.; Hu, J.; Hu, K.; Eitel, K.; Gmeiner, P.; Wess, J.; Kobilka, B. K.; Shoichet, B. K. Muscarinic receptors as model targets and antitargets for structure-based ligand discovery Mol. Pharmacol. 2013, 84, 528-540 10.1124/mol.113.087551
193. Rodriguez, D.; Brea, J.; Loza, M. I.; Carlsson, J. Structure-based discovery of selective serotonin 5-HT1B receptor ligands Structure 2014, 22, 1140-1151 10.1016/j.str.2014.05.017
194. Schmidt, D.; Bernat, V.; Brox, R.; Tschammer, N.; Kolb, P. Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-target docking ACS Chem. Biol. 2015, 10, 715-724 10.1021/cb500577j
195. Weiss, D. R.; Ahn, S.; Sassano, M. F.; Kleist, A.; Zhu, X.; Strachan, R.; Roth, B. L.; Lefkowitz, R. J.; Shoichet, B. K. Conformation guides molecular efficacy in docking screens of activated beta-2 adrenergic G protein coupled receptor ACS Chem. Biol. 2013, 8, 1018-1026 10.1021/cb400103f
196. Brogi, S.; Tafi, A.; Desaubry, L.; Nebigil, C. G. Discovery of GPCR ligands for probing signal transduction pathways Front. Pharmacol. 2014, 5, 255 10.3389/fphar.2014.00255
197. Mohr, K.; Schmitz, J.; Schrage, R.; Trankle, C.; Holzgrabe, U. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors Angew. Chem., Int. Ed. 2013, 52, 508-516 10.1002/anie.201205315
198. Allegretti, M.; Cesta, M. C.; Locati, M. Allosteric modulation of chemoattractant receptors Front. Immunol. 2016, 7, 170 10.3389/fimmu.2016.00170
199. Zarbock, A.; Allegretti, M.; Ley, K. Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice Br. J. Pharmacol. 2008, 155, 357-364 10.1038/bjp.2008.270
200. Lane, J. R.; Chubukov, P.; Liu, W.; Canals, M.; Cherezov, V.; Abagyan, R.; Stevens, R. C.; Katritch, V. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors Mol. Pharmacol. 2013, 84, 794-807 10.1124/mol.113.088054
201. Fronik, P.; Gaiser, B. I.; Sejer Pedersen, D. Bitopic ligands and metastable binding sites: opportunities for G protein-coupled receptor (GPCR) medicinal chemistry J. Med. Chem. 2017, 60, 4126 10.1021/acs.jmedchem.6b01601
202. Bock, A.; Merten, N.; Schrage, R.; Dallanoce, C.; Batz, J.; Klockner, J.; Schmitz, J.; Matera, C.; Simon, K.; Kebig, A.; Peters, L.; Muller, A.; Schrobang-Ley, J.; Trankle, C.; Hoffmann, C.; De Amici, M.; Holzgrabe, U.; Kostenis, E.; Mohr, K. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling Nat. Commun. 2012, 3, 1044 10.1038/ncomms2028
203. Silvano, E.; Millan, M. J.; Mannoury la Cour, C.; Han, Y.; Duan, L.; Griffin, S. A.; Luedtke, R. R.; Aloisi, G.; Rossi, M.; Zazzeroni, F.; Javitch, J. A.; Maggio, R. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors Mol. Pharmacol. 2010, 78, 925-934 10.1124/mol.110.065755
204. Lane, J. R.; Donthamsetti, P.; Shonberg, J.; Draper-Joyce, C. J.; Dentry, S.; Michino, M.; Shi, L.; Lopez, L.; Scammells, P. J.; Capuano, B.; Sexton, P. M.; Javitch, J. A.; Christopoulos, A. A new mechanism of allostery in a G protein-coupled receptor dimer Nat. Chem. Biol. 2014, 10, 745-752 10.1038/nchembio.1593
205. Garnock-Jones, K. P. Brexpiprazole: a review in schizophrenia CNS Drugs 2016, 30, 335-342 10.1007/s40263-016-0325-8
206. Sengupta, D.; Joshi, M.; Athale, C. A.; Chattopadhyay, A. What can simulations tell us about GPCRs: integrating the scales Methods Cell Biol. 2016, 132, 429-452 10.1016/bs.mcb.2015.11.007
207. Rodriguez, D.; Gutierrez-de-Teran, H. Computational approaches for ligand discovery and design in class-A G protein-coupled receptors Curr. Pharm. Des. 2013, 19, 2216-2236 10.2174/1381612811319120009
208. Kaczor, A. A.; Rutkowska, E.; Bartuzi, D.; Targowska-Duda, K. M.; Matosiuk, D.; Selent, J. Computational methods for studying G protein-coupled receptors (GPCRs) Methods Cell Biol. 2016, 132, 359-399 10.1016/bs.mcb.2015.11.002
209. Ciancetta, A.; Sabbadin, D.; Federico, S.; Spalluto, G.; Moro, S. Advances in computational techniques to study GPCR-ligand recognition Trends Pharmacol. Sci. 2015, 36, 878-890 10.1016/j.tips.2015.08.006
210. Motlagh, H. N.; Wrabl, J. O.; Li, J.; Hilser, V. J. The ensemble nature of allostery Nature 2014, 508, 331-339 10.1038/nature13001
211. Dror, R. O.; Pan, A. C.; Arlow, D. H.; Borhani, D. W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D. E. Pathway and mechanism of drug binding to G-protein-coupled receptors Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 13118-13123 10.1073/pnas.1104614108